Efficacy and Safety Study of Seroquel SR in the treatment of Generalized Anxiety Disorder - SILVER
Study identifier:D1448C00011
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2005-005054-46
CTIS identifier:N/A
Study Complete
Official Title
An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER)
Medical condition
Generalized Anxiety Disorder
Phase
Phase 3
Healthy volunteers
No
Study drug
Quetiapine fumarate, Paroxetine
Sex
All
Actual Enrollment
800
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 May 2006
Primary Completion Date: -
Study Completion Date: 01 May 2007
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Seroquel Medical Science Director
AstraZeneca
